Published 1 month ago • loading... • Updated 1 month ago

Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

Akeso, Inc. announced long-term survival data from a Phase II study of cadonilimab monotherapy in recurrent or metastatic cervical cancer patients who failed prior chemotherapy, presented at ESGO 2026 by Professor Wu Xiaohua.
Among patients who achieved complete response, the 24-month overall survival rate was 100%, with median overall survival not reached.
Median progression-free survival was not reached, with a 12-month progression-free survival rate of 84.6%.
Updated data showed durable survival benefits with 24-month overall survival rates of 40.9% across all patients, confirming cadonilimab's long-term disease control ability.

Insights by Ground AI

47 Articles

Bennington Banner

+45 Reposted by 45 other sources

Center

Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results

HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent…

1 month ago

Read Full Article

cancernetwork.com

Cadonilimab Yields 100% 24-Month OS in Recurrent Cervical Cancer Population

Cadonilimab monotherapy did not yet reach the median OS or PFS at the time of data cutoff for these patients with recurrent or metastatic cervical cancer.

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year